The 2nd TPD 2019 is a specifically dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitalize on the emerging therapeutic class of protein degradation.
As the drug discovery opportunity promised within the proteome becomes a reality and previously "undruggable" targets are reached, the 2nd TPD Summit returns for 2019.
This premier event exists not only to drive forward the translation of first generation of PROTACS and molecular glues into the clinic, but to stimulate the discussion of next generation protein degraders that harness different modalities, target highly desirable targets and capitalize on degradation pathways, beyond the ubiquitin proteasome system.
Full Access: Conference + Workshop Day - Standard rate ( bird available) : USD 4299.0,
Conference Only - Standard rate (Early birds available) : USD 2999.0
Speakers: Craig Crews - American Cancer Society Professor of MCDB - Yale University, Alessio Ciulli - Professor of Chemical And Structural Biology - University of Dundee, Mikihiko Naito - Chief, Division of Molecular Target and Gene Therapy Products - Japan National Institute of Health Sciences, Raymond Deshaies - Senior Vice President for Global Research - Amgen, Lawrence Hamann - Corporate Vice President, Chemistry - Celgene, Darryl McConnell - Vice President and Research Site Head Austria - Boehringer Ingelheim, Adam Gilbert - Senior Director, Discovery Sciences, Design And Synthesis Sciences - Pfizer, John Houston - Chief Executive Officer - Arvinas, Stewart Fisher - Chief Scientific Officer - C4 Therapeutics, Nello Mainolfi - Founder and Chief Scientific Officer - Kymera Therapeutics